You are here

Takeda

Ovid's lead drug shows promising efficacy signal in Fragile X syndrome study, but optimal dosing regimen is unclear for path forward

Endpoints

Fri, 05/8/20 - 10:34 am

Ovid Therapeutics

Fragile X syndrome

clinical trials

Takeda gets FDA breakthrough therapy status for mobocertinib to treat certain type of lung cancer

Pharmaceutical Business Review

Tue, 04/28/20 - 11:45 pm

metastatic non-small cell lung cancer

Takeda licenses ProThera plasma drug for use in inflammatory conditions

Fierce Biotech

Fri, 04/24/20 - 11:07 am

ProThera Biologics

inflammatory diseases

plasma-based pharmaceuticals

Takeda to sell European OTC business to cut debts

Pharmaforum

Fri, 04/24/20 - 10:53 am

Takeda, CSL forge coronavirus alliance, forgoing their own drugs in the process

BioPharma Dive

Wed, 04/8/20 - 10:33 am

drug development

Biopharma acquisitions slow, but it's not Covid-19's fault yet

EP Vantage

Wed, 04/8/20 - 10:28 am

Gilead Sciences

ANI Pharmaceuticals

Amerigen Pharma

Takeda and Evotec Enter into Gene Therapy Research Alliance

BioSpace

Mon, 04/6/20 - 09:43 pm

Takeda signs $882m rare disease alliance with Oxford biotech Evox

Pharmaforum

Fri, 03/27/20 - 10:34 am

Evox Therapeutics

Bayer inks up with “small” Indian biotech for new approach at an old target

Endpoints

Mon, 03/23/20 - 11:31 am

2 newer multiple myeloma drugs fall short in bid for wider market

BioPharma Dive

Tue, 03/10/20 - 11:58 am

Multiple Myeloma

clinical trials

Bristol-Myers Squibb

These nine companies are working on coronavirus treatments or vaccines — here’s where things stand

Marketwatch

Sun, 03/8/20 - 11:26 pm

Gilead Sciences

Moderna Therapeutics

Vir Biotchnology

Takeda and Arcturus join hunt for coronavirus therapies

Pharmaforum

Thu, 03/5/20 - 10:50 am

drug development

Can reformulation of an AstraZeneca castoff rival Takeda's new heartburn drug? Here's a $26M bet on yes

Endpoints

Wed, 03/4/20 - 07:55 pm

Takeda Acquires Celiac-Focused PvP Biologics in Deal Worth $330 Million

BioSpace

Wed, 02/26/20 - 10:34 am

Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC

Pharmaceutical Business Review

Tue, 02/25/20 - 10:19 am

priority review

non-small cell lung cancer

Novimmune unit nabs Takeda milestone payment for hemophilia work

Fierce Biotech

Fri, 02/14/20 - 10:40 am

Light Chain Bioscience

Takeda invests in patient-centric data firm Seqster

Pharmaforum

Thu, 02/13/20 - 10:42 am

MD Anderson emerges with strong evidence for natural killer cell therapy, and Takeda looks like a winner

Endpoints

Thu, 02/6/20 - 11:50 am

natural killer cell therapy

Takeda Pharmaceutical Raises Its Profit Outlook

Motley Fool

Tue, 02/4/20 - 11:21 pm

Takeda puts Shire biologics plant with 200 employees on the block

Fierce Pharma

Fri, 01/31/20 - 11:00 am

drug manufacturing

Pages